Ginkgo Bioworks (NYSE:DNA) specializes in cell programming, leveraging synthetic biology to design, develop, and manufacture organisms for a variety of applications including pharmaceuticals, agriculture, and biotechnology. Aimed at solving some of the world's most pressing challenges, its projects span across developing antibiotics, biofuels, and more sustainable food solutions. Ginkgo Bioworks operates with the objective to make biology as easy to engineer as computers, envisioning a future where its technology can bring about significant advancements in health, energy, and environmental sustainability.